Hotelbeds owner HBX Group sets indicative IPO share price at 11.5 euros
Hotelbeds owner HBX Group set the indicative share price for its initial public offering at 11.50 euros ($11.93) per share, ...
Maze Therapeutics begins Phase 2 trial for kidney disease drug
Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...
VCCircle49 分钟
Creador-backed Paras Healthcare faces valuation headwinds ahead of IPO
Paras Healthcare Ltd may settle for a lower valuation in its upcoming initial public offering than it initially ...
Association of Optometrists54 分钟
“Our personal approach to pre-reg recruitment allows us to ensure a better candidate ...
OT heard how Duncan & Todd has expanded its pre-registration recruitment programme to welcome students from Ulster University ...